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A B S T R A C T
Testosterone is converted to dihyrotestosterone by two isoenzymes of 5a-reductase. Finasteride and dutasteride are
5a-reductase inhibitors commonly used in the treatment of benign prostatic hyperplasia. We compared indices of bone
mineral density in 50 men treated with finasteride, 50 men treated with dutasteride and 50 men as control. Bone mineral
density of spine and hip were measured using dual energy X-ray absorptiometry. Bone formation was assessed by mea-
suring serum osteocalcin and bone resorption by measuring serum C-terminal telopeptide of collagen type 1. In addition
serum total testosteron and estradiol were determined. The dutasteride group had significantly higher mean bone min-
eral density, mean bone mineral content, mean T score, mean Z score at femoral neck and mean total hip Z score than
control. Mean total testosterone and estradiol levels were higher in the dutasteride group. There were no significant dif-
ferences between the groups in lumbar spine bone density parameters or bone turnover markers. Our results provide evi-
dence that long-term 5a-reductase suppression does not adversely affect bone mineral density. Dutasteride therapy could
have beneficial effect on bone density.
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Introduction
Current clinical practice guidelines recommend 5a-
-reductase inhibitors (5ARIs), either alone or in combi-
nation with alpha-blockers, as appropriate treatment op-
tions for benign prostatic hyperplasia BPH1. The clinical
efficacy of 5ARIs in the treatment of BPH has been
firmly established and supported with scientific eviden-
ces2,3. A marked reduction in prostate volume, improve-
ment in symptoms associated with BPH, a significant re-
duction in the risk of acute urinary retention and the
need for BPH related surgery are all beneficial effects of
5ARIs administration4,5. The two widely available 5ARIs
are finasteride and dutasteride. Each drug induces mar-
ked dihydrotestosterone (DHT) suppression, which is the
primary androgen responsible for prostate growth6,7.
Testosterone is converted to more potent androgen, DHT
by two isoenzymes of 5a-reductase. The type 2 isoen-
zyme predominates in normal and BPH tissue and is in-
hibited by finasteride, which decreases serum concentra-
tions of DHT by approximately 70%8. Dutasteride, a dual
5ARI inhibits both type 1 and type 2 isoenzyms, leading
to a 95% decrease in serum DHT concentrations9. This
difference may be important during long term treat-
ment.
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The long-term effects of altering the androgen bal-
ance through 5a-reductase inhibition on other androgen
responsive tissues such as bone are less well established.
Numerous studies have clarified complex effects of sex
hormones on bone cells. The relative role of the androgen
receptor, estrogen receptor a and estrogen receptor b in
mediating the effect of androgens or their metabolites on
bone tissue has been debated10. Androgen deficiency in
men is associated with premature bone loss and in-
creased frequency of osteoporotic fractures11. It has been
demonstrated that human osteoblast-like cells express
predominantly 5a-reductase type 111. Although there are
evidences that androgens exert profound effect on the
homeostasis of mature bone in men, the relative impor-
tance of androgens and estrogens for bone turnover re-
mains unresolved10. There is increasing evidence that at
least part of the effects of androgen in men can be ex-
plained by their aromatization into estrogens12. Despite
dramatic decrease in serum DHT, current scientific evi-
dence does not suggest significant impact of 5ARIs on
bone tissue despite biological plausibility in either direc-
tion. Clinical studies with a type 2 5ARI, finasteride pro-
vide evidence that inhibition of type 2 5a-reductase does
not adversely affect bone mineral density (BMD), the
lack of significant changes in the bone markers is consis-
tent with minimal effect on bone metabolism13,14,17. Be-
cause of near complete inhibition of 5a-reductase, duta-
steride has a far greater potential to interfere with male
skeletal homeostasis. Recent finding that type 1 5a-redu-
ctase is predominantly expressed in osteoblast supports
the absence of effect on bone in clinical studies with type
2 5ARI (finasteride) but rise question about dutasteride
effect on bone through inhibition of type 1 5a-reduc-
tase11. In this study for the first time we examined the ef-




The study included a total of 150 male subjects 60 to
78 years old who suffered from BPH. All subjects were
regular patients of Department of Urology (University
Hospital of Rijeka, Rijeka, Croatia). Finasteride group in-
cluded 50 subjects who were treated with finasteride 5
mg daily for a period of 24 to 48 months. Dutasteride
group included 50 subjects who were treated with duta-
steride 0.5 mg daily for a period of 24 to 48 months.
Finasteride and dutasteride group were compared with
control group which consisted of 50 subjects who had
never been treated with 5ARI and were comparable with
both groups considering age, body mass index (BMI) and
physical activity.
All subjects were free of clinically significant systemic
or other disorder which affect bone metabolism like dia-
betes mellitus, chronic renal failure, parathyroid disor-
der; smoking; heavy alcohol use; use of medications inclu-
ding anabolic steroids, antiandrogens, estrogen, glucocor-
ticoids, diuretics, seizure medications, warfarin, calcium
or vitamin D supplements as determined by patients
medical history, physical examination, clinical laboratory
test results and baseline questionnaire completed by all
subjects. Informed consent was obtained from all sub-
jects and the institutional ethics committee approved
this study.
Measurements
BMD was measured at the lumbar spine: anteropos-
terior view (L1-L4); lateral view (L2-L3) and in the
nondominant hip by dual energy x-ray absorptiometry
using a Hologic densitometer QDR DELPHI-W#70616W
(Hologic, Bedford, USA). Bone densitometry results are
reported as bone mineral density (BMD, mg/cm²), bone
mineral content (BMC, mg), T score (compares the BMD
to the mean for young normal males) and Z score (com-
pares it with age-matched controls)17. T score and Z score
are expressed as the number of standard deviations (SD)
values by which a given result differs from the mean
value for young men and men of equal age respectively.
All subjects were assessed by same machine by experi-
enced dual energy X-ray technologists who were provided
with study specific standard operating procedure. Instru-
ment-specific normative database was used. All bone
density scans were analyzed for acceptability considering
artifacts, compression fractures or other confounding
factors.
Serum total testosterone and estradiol were measu-
red by electrochemiluminescence immunoassay (ECLIA)
using a analyzer Elecsys 2010 (Roche, Meinheim, Ger-
many). The normal range is 6.68–25.7 nmol/L for total
testosterone and 28–156 pmol/L for estradiol. The bone
turnover markers serum osteocalcin and serum C-termi-
nal telopeptide of type 1 collagen (S-CTX) were mea-
sured by ECLIA using analyzer Cobas 601e 2009 (Roche,
Meinheim, Germany). The normal range is 14–46 mg/L for
osteocalcin and <0.704 mg/L for S-CTX. For hormone
and bone turnover markers blood was drawn in the
morning and measurements were performed at a central
laboratory (University Hospital of Rijeka, Rijeka, Croatia).
Statistical analysis
The collected data were statistically evaluated using
data analysis software system STATISTICA 8.0 (StatSoft
Inc,Tulsa, OK, USA). The continuous variables were
checked for normality of distributions (by Kolmogorov-
-Smirnov and Shapiro-Wilks tests) and presented by mean
and standard deviation. Comparisons of variables between
groups were made using ANOVA test, while post-hoc
comparisons using Sheffé test. The level of statistical sig-
nificance was set at 0.05 in all analyses.
Results
Base-line characteristics of hormonal
levels and bone turnover markers
There were no significant differences among fina-
steride, dutasteride and control group in age and BMI.
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The dutasteride group had higher mean serum total tes-
tosterone levels than finasteride (p<0.001) and control
(p=0.006).The mean serum estradiol levels were higher
in the dutasteride group than finasteride (p=0.015) and
control (p<0.001). There were no significant differences
between finasteride and control group in mean serum to-
tal testosterone and estradiol levels. There were no signi-
ficant differences among finasteride, dutasteride and con-
trol group in serum bone turnover markers; osteocalcin
and S-CTX (Table 1).
Bone densitometry parameters
All bone density parameters mean values at femoral
neck were significantly higher in the dutasteride group
than control: BMD (p=0.027), BMC (p=0.020), T score
(p=0.028) i Z score (p=0.011). There were no significant
differences between dutasteride and finasteride group in
bone density parameters mean values at femoral neck:
BMD (p=0.274), BMC (p=0.147), T score (p=0.277) i Z
score (p=0.243). There were no significant differences
between finasteride and control group in bone density
parameters mean values at femoral neck: BMD (p=
0.552), BMC (p=0.687), T score (p=0.549) i Z score
(p=0.394). The mean total hip Z score was also signifi-
cantly higher in the dutasteride group than control (p=
0.027). There were no significant differences between
dutasteride and finasteride group in the mean total hip Z
score (p=0.631). There were no significant differences
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TABLE 1
COMPARISON OF PATIENT CHARACTERISTICS, HORMONES AND BONE TURNOVER MARKERS (X±SD)
Parameter
Group
Control (N=50) Finasteride (N=50) Dutasteride (N=50)
Age (years) 68±4 69±5 70±5
BMI (kg/m2) 26.5±2.6 26.6±2.2 26.8±2.5
Total testosterone (nmol/L) 17.1±6.8 16.4±4.0 20.3±2.9*§
Estradiol (pmol/L) 82.7±29.9 90.6±52.7 116.1±44.8*§
Osteocalcin (mg/L) 17.7± 5.6 17.6±4.6 17.0±2.9
S-CTX (mg/L) 0.25±0.1 0.22±0.08 0.22±0.08
BMI – body mass index, S-CTX – serum C-terminal telopeptide of type 1 collagen; * comparison between dutasteride and control group,
p<0.05; § comparison between dutasteride and finasteride group, p<0.05
TABLE 2
COMPARISON OF BONE DENSITOMETRY PARAMETERS (MEAN±SD)
Parameter
Group
Control (N=50) Finasteride (N=50) Dutasteride (N=50)
Lumbar spine AP (L1-L4)
BMC (g) 74.7±15.3 76.7±19.5 77.0±18.1
BMD (g/cm2) 1.05±0.16 1.08±0.22 1.08±0.18
T score –0.34±1.5 –0.05±2.0 –0.14±1.6
Z score 0.54±1.5 0.85±2.0 0.77±1.6
Lumbar spine Lat (L2,L3)
BMC (g) 19.9±5.1 20.8±5.6 20.5±4.3
BMD (g/cm2) 0.76±0.15 0.80±0.20 0.77±0.14
Femoral neck
BMC (g) 5.26±0.9 5.45±1.2 5.90±1.3*
BMD (g/cm2) 0.87±0.12 0.90±0.14 0.94±0.16*
T score –0.47±0.9 –0.24±1.0 0.09±1.2*
Z score 0.69±0.9 0.96±1.0 1.30±1.1*
Total hip
BMC (g) 48.40±7.1 49.79±8.6 51.35±10.3
BMD (g/cm2) 1.02±0.12 1.06±0.13 1.08±0.16
T score –0.11±0.81 0.16±0.88 0.33±1.03
Z score 0.53±0.8 0.85±0.9 1.02±1.0*
AP – anteroposterior view, Lat – lateral view, BMC – bone mineral content, BMD – bone mineral density; * comparison between
dutasteride and control group, p<0.05
between finasteride and control group in the mean total
hip Z score (p=0.218). There were no significant differ-
ences among finastride, dutasteride and control group in
mean values for total hip BMD, BMC and T score. There
were no significant differences among finasteride, duta-
steride and control group in mean values of lumbar spine
bone density parameters. Analyzed parameters were BMD,
BMC, T score, Z score in anteroposterior view (L1-L4)
and BMD, BMC in lateral view (L2, L3) (Table 2).
Discussion and Conclusion
Although 5ARIs in the treatment of BPH have been
used for 20 years, few studies have investigated the skel-
etal effects of these drugs. The results of studies designed
to address the impact of type 2 5a-reductase inhibition
with finasteride on bone tissue in men are consistent in
showing no effect on BMD or bone turnover markers de-
spite marked serum DHT suppression13–16. Our finding
that long term inhibition of type 2 5a-reductase with
finasteride does not adversely affect bone mineral den-
sity in older men with BPH is in agreement with those
studies. Important finding that type 1, not type 2 5a-re-
ductase is predominantly expressed in osteoblasts might
explain absence of effect on bone in these studies11.
We found that older men chronically treated with
dutasteride because of BPH have significantly greater
bone mineral density parameters (BMD, BMC, T score
and Z score) at femoral neck and also total hip Z score
than controls. The impact of dutasteride, a dual type 1
and type 2 5ARI on bone tissue is less well-established,
because studies are currently lacking. In contrast to our
finding, Amory at al. showed that dutasteride did not
have significant effects on BMD despite profound (94%)
serum DHT suppression16. In interpreting these results,
however, it should be considered that subjects in this
study were young man, duration of 5a-reductase inhibi-
tion was 1 year and only total hip, not femoral neck BMD
was measured.
The dutasteride treated older men in our study had
significantly higher mean serum total testosteron and
estradiol. The relative roles of testosterone, DHT and
estradiol in homeostasis of mature bone are not clear.
Testosterone levels have been shown to be directly corre-
lated with BMD in older men, although serum levels of
estradiol were more strongly correlated17. Higher serum
levels of estradiol in our study may be due to shunting of
testosterone through the aromatization pathway. Serum
DHT levels were not measured in our study and are
known from previous studies16. Our results suggest that
serum estradiol plays a major role in maintenance of
BMD in older men, which could be true especially for cor-
tical bone compartment. Therefore conversion of testos-
terone to DHT may not be necessary for the effect of an-
drogens on BMD in older men. We found no differences
in spine BMD between studied groups. It is possible that
effects of 5a-reductase inhibition on cancellous and corti-
cal bone are different. It is known that sex hormones act
on different way on two different bone compartments10.
The lack of significant differences between groups in
bone turnover markers in our study is consistent with
most other studies13,16.
Our findings imply that dutasteride could have oste-
protective effect on cortical bone but whether and to
what extent effects on bone density may translate in clin-
ical benefits need further investigation. In a recent study
exposure to 5ARIs may lower the risk of hip fracture18.
Together with long term studies using selective modula-
tion of androgen and estrogen action, to clarify local hor-
mone levels and interactions in bone tissue may be an
important part for a comprehensive picture.
Long term use of 5ARIs in treatment of BPH in older
men does not adversely affect bone mineral density. Fur-
thermore dutasteride could have osteprotective effect on
cortical bone health in terms of bone densitometry pa-
rameters. Although long term studies are needed, our
data suggest that dutasteride could prevent bone loss
and provide protection against osteoporosis in older men.
R E F E R E N C E S
1. MADERSBACHER S, ALIVIZATOS G, NORDLING J, SANZ CR,
EMBERTON M, DE LA ROSETTE JJ, Eur Urol, 46 (2004) 547. — 2. Mc-
CONNELL JD, ROEHRBORN CG, BAUTISTA OM, N Engl J Med, 349
(2003) 2387. — 3. ROEHRBORN CG, SIAMI P, BARKIN J, Eur Urol, 57
(2010) 123. DOI: 10.1016/j.eururo.2009.09.035. — 4. McCONNELL JD,
BRUSKEWITZ R, WALSH P, ANDRIOLE G, LIEBER M, HOLTGREWE
HL, N Engl J Med, 338 (1998) 557. — 5. DEBRUYNE F, BARKIN J, VAN
ERPS P, REIS M, TAMMELA TL, ROEHRBORN C, Eur Urol, 46 (2004)
488. — 6. McCONNELL JD, Br J Urol, 76 (Suppl 1) (1995) 5. — 7. CAR-
SON C, RITTMASTER R, Urology, 61 (2003) 2. — 8. RITTMASTER RS,
LEMAY A, ZWICKER H, CAPIZZI TP, WINCH S, MOORE E, J Clin En-
dokrinol Metab, 75 (1992) 484. — 9. CLARK RV, HERMANN DJ, CUN-
NINGHAM GR, WILSON TH, MORRILL BB, HOBBS S, Clin Endocrinol
Metab, 89 (2004) 2179. — 10. VANDERSCHUEREN D, VANDENPUT L,
BOONEN S, LINDBERG MK, BOUILLON R, OHLASON C, Endocr Rev,
25 (2004) 389. — 11. ISSA S, SCHNABEL D, FEIX M, J Clin Endocrinol
Metab, 87 (2002) 5401. — 12. KHOSLA S, MELTON III LJ, RIGS BL, J
Clin Endocrinol Metab, 87 (2002) 1443. — 13. TOLLIN SR, ROSEN HN,
ZUROWSKI K, J Clin Endocrinol Metab, 81 (1996) 1031. — 14. MATSU-
MOTO AM, TENOVER L, MCCLUNG M, J Urol, 167 (2002) 2105. — 15.
MATZKIN H, CHEN J,WEISMAN Y, GOLDRAY D, PAPPAS F, JAC-
CARD N, BRAF Z, Clin Endocrinol, 37 (1992) 432. — 16. AMORY JK,
ANAWALT BD, MATSUMOTO AM, J Urol, 179 (2008) 2333. DOI: 10.
1016/j.juro.2008.01.145. — 17. KHOSLA S, MELTON LJ III, ATKINSON
EJ, O'FALLON WM, J Clin Endocrinol Metab, 86 (2001) 3555. — 18. JA-
COBSEN SJ, CHEETHAM TC, HAQUE R, SHI JM, LOO RK, JAMA, 300
(2008) 1660. DOI: 10.1001/jama.300.14.1660.
J. [panjol
University of Rijeka, School of Medicine, Department of Urology, Bra}e Branchetta 20, 51000 Rijeka, Croatia
e-mail: josip.spanjol@medri.uniri.hr
I. Radin Ma~ukat et al.: Effect of 5a-reductase Inhibition on Bone Density, Coll. Antropol. 38 (2014) 3: 835–839
838
UTJECAJ INHIBICIJE 5a-REDUKTAZE S FINASTERIDOM I DUTASTERIDOM NA GUSTO]U
KOSTIJU KOD STARIJIH MU[KARACA S BENIGNOM HIPERPLAZIJOM PROSTATE
S A @ E T A K
Testosteron se pretvara u dihidrotestosteron putem dva izoenzima 5a-reduktaze. Finasterid i dutasteride su 5a-re-
duktaza inhibitori koji se obi~no koriste u lije~enju benigne prostati~ne hiperplazije1–7. Usporedili smo indekse mine-
ralne gusto}e kosti u 50 mu{karaca lije~enih finasteridom, 50 mu{karaca lije~enih s dutasteridom i 50 nelije~enih
mu{karaca koji su predstavljali kontrolnu skupinu. Ko{tana mineralna gusto}a kralje`nice i kuka mjerene su pomo}u
dvostruke rendgenske apsorpciometrije. Ko{tani metabolizam procijenili smo mjerenjem serumskog osteokalcina (po-
kazatelj stvaranja nove kosti) i mjerenjem serumskog C-terminalnog telopeptida kolagena tipa 1 (pokazatelj razgradnje
kostiju). Tako|er. Smo odredili ukupni serumski testosteron i estradiol. Dutasterid skupina imala je zna~ajno vi{u
srednju gusto}u kostiju, srednji sadr`aj minerala u kostima. Srednja vrijednost serumskog testosterona i estradiola u
krvi bila je vi{a u dutasterid grupi. Nije bilo zna~ajne razlike izme|u skupina u mineralnoj gusto}i slabunske kra-
lje`nice. Na{i rezultati pru`aju dokaze kako dugoro~na primjena inhibitora 5a-reduktaze ne utje~e nepovoljno na mine-
ralnu gusto}u kostiju. Terapija dutasteridom mo`e imati blagotvoran u~inak na kosti.
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